CTI BioPharma Corp.'s (CTIC) Drug News Brings in Option Bulls

A positive development with a cancer drug sent bulls to CTI BioPharma Corp (CTIC)

Digital Content Group
Feb 4, 2015 at 11:01 AM
facebook twitter linkedin

CTI BioPharma Corp (NASDAQ:CTIC) jumped 4.6% yesterday, closing at $2.29, after an independent data monitoring committee recommended continuing a clinical study of its ovarian cancer drug Opaxio. Options bulls ran with the news, picking up calls at three times the normal single-session rate.

Receiving the most action by far was the April 2 call, where it seems buy-to-open activity took place. These speculators are hoping for CTIC to extend its run above $2 through the close on Friday, April 17, when the options expire.

On the sentiment front, analysts are all-in on CTIC. All six covering brokerage firms rate the stock a "strong buy." Plus, the equity's average 12-month price target of $5.08 is more than double its current perch, and stands in territory not charted since May 2012.

Analysts have kept this positive outlook on CTI BioPharma Corp (NASDAQ:CTIC) despite its technical struggles. Since its mid-September high of $2.93, the security has lost 24.2%. At last check, CTIC was down 3.1% at $2.22.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners